Trial · NCT03050307
Results by group18
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 18 of 18
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With Endoscopically Confirmed Healing of Gastric Ulcers (GUs) at Weeks 4 or 8 | TAK-438 20 mg | 91.1 | 95% Confidence Interval 84.193 to 95.635 | percentage of participants | |
| Percentage of Participants With Endoscopically Confirmed Healing of Gastric Ulcers (GUs) at Weeks 4 or 8 | Lansoprazole 30 mg | 94.7 | 95% Confidence Interval 88.896 to 98.044 | percentage of participants | |
| Percentage of Helicobacter Pylori Infected (HP+) Participants With Successful HP Eradication After 4 or 8 Weeks of Treatment | TAK-438 20 mg | 88.0 | 95% Confidence Interval 78.439 to 94.363 | percentage of participants | |
| Percentage of Helicobacter Pylori Infected (HP+) Participants With Successful HP Eradication After 4 or 8 Weeks of Treatment | Lansoprazole 30 mg | 80.8 | 95% Confidence Interval 69.921 to 89.099 | percentage of participants | |
| Percentage of Participants With Endoscopically Confirmed Healing of GU at Week 4 | TAK-438 20 mg | 76.1 | 95% Confidence Interval 67.035 to 83.788 | percentage of participants | |
| Percentage of Participants With Endoscopically Confirmed Healing of GU at Week 4 | Lansoprazole 30 mg | 82.1 | 95% Confidence Interval 73.777 to 88.738 | percentage of participants | |
| Percentage of Participants With Post-treatment Resolution of Gastrointestinal Symptoms Associated With GU | TAK-438 20 mg | Epigastric Pain (Postprandial) | 78.9 | 95% Confidence Interval 54.435 to 93.948 | percentage of participants |
| Percentage of Participants With Post-treatment Resolution of Gastrointestinal Symptoms Associated With GU | Lansoprazole 30 mg | Epigastric Pain (Postprandial) | 80.0 | 95% Confidence Interval 59.296 to 93.169 | percentage of participants |
| Percentage of Participants With Post-treatment Resolution of Gastrointestinal Symptoms Associated With GU | TAK-438 20 mg | Epigastric Pain (Fasting/Nocturnal) | 85.0 | 95% Confidence Interval 70.165 to 94.290 | percentage of participants |
| Percentage of Participants With Post-treatment Resolution of Gastrointestinal Symptoms Associated With GU | Lansoprazole 30 mg | Epigastric Pain (Fasting/Nocturnal) | 80.5 | 95% Confidence Interval 65.133 to 91.179 | percentage of participants |
| Percentage of Participants With Post-treatment Resolution of Gastrointestinal Symptoms Associated With GU | TAK-438 20 mg | Abdominal Bloating | 81.3 | 95% Confidence Interval 54.354 to 95.953 | percentage of participants |
| Percentage of Participants With Post-treatment Resolution of Gastrointestinal Symptoms Associated With GU | Lansoprazole 30 mg | Abdominal Bloating | 65.2 | 95% Confidence Interval 42.734 to 83.624 | percentage of participants |
| Percentage of Participants With Post-treatment Resolution of Gastrointestinal Symptoms Associated With GU | TAK-438 20 mg | Nausea/Vomiting | 100.0 | 95% Confidence Interval 100.0 to 100.0 | percentage of participants |
| Percentage of Participants With Post-treatment Resolution of Gastrointestinal Symptoms Associated With GU | Lansoprazole 30 mg | Nausea/Vomiting | 100.0 | 95% Confidence Interval 100.0 to 100.0 | percentage of participants |
| Percentage of Participants With Post-treatment Resolution of Gastrointestinal Symptoms Associated With GU | TAK-438 20 mg | Heartburn | 95.8 | 95% Confidence Interval 78.880 to 99.895 | percentage of participants |
| Percentage of Participants With Post-treatment Resolution of Gastrointestinal Symptoms Associated With GU | Lansoprazole 30 mg | Heartburn | 85.7 | 95% Confidence Interval 67.335 to 95.966 | percentage of participants |
| Percentage of Participants With Post-treatment Resolution of Gastrointestinal Symptoms Associated With GU | TAK-438 20 mg | Lack of Appetite | 77.8 | 95% Confidence Interval 39.991 to 97.186 | percentage of participants |
| Percentage of Participants With Post-treatment Resolution of Gastrointestinal Symptoms Associated With GU | Lansoprazole 30 mg | Lack of Appetite | 90.0 | 95% Confidence Interval 55.498 to 99.747 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03050307/results